luspatercept
Celgene and Acceleron’s blood disorder drug smashes endpoints at Phase 3
July 11, 2018Research and Development Acceleron, Celgene, beta-thalassemia, luspatercept, pharma
Celgene and Acceleron have lifted the curtain on new Phase 3 data for their erythroid maturation agent (EMA) luspatercept, confirming …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
Highlighting the value of lab research for healthcare innovation
November 2, 2026
